Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Indirect comparison of efficacy of zanubrutinib vs ibrutinib for the treatment of relapsed/refractory mantle cell lymphoma

View Full Paper
Ask AI
Bookmark
Share

Authors

TEToby EyreLMLeyla MohseninejadLBLianne Barnieh

Discussion

Loading...

Member takes

Overview

Indirect comparison reveals significant improvement in progression-free survival for zanubrutinib vs ibrutinib in relapsed mantle cell lymphoma.

Key Points

  • Zanubrutinib significantly improves progression-free survival compared to ibrutinib in patients with relapsed mantle cell lymphoma.
  • Hazard ratios indicated a notable PFS benefit for zanubrutinib: 0.54 (before matching) and 0.63 (after matching).
  • Clinical trials included the analysis of two single-arm trials for zanubrutinib and four studies for ibrutinib, validating the efficacy comparison.
  • Results highlight the effectiveness of zanubrutinib, suggesting therapeutic advantages over ibrutinib in treating mantle cell lymphoma.

Cite This Study

Eyre et al. (2025) studied this question.

synapsesocial.com/papers/69362f5a4fa91c937236db27https://doi.org/10.1182/blood-2025-5365
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Zanubrutinib versus acalabrutinib indirect treatment comparison in relapsed or refractory mantle cell lymphoma2025
  2. 2A matching-adjusted indirect comparison (MAIC) of zanubrutinib vs venetoclax + ibrutinib in treatment-naive chronic lymphocytic leukemia (CLL)2025
  3. 3Efficacy and safety of zanubrutinib-containing regimens in patients with newly diagnosed Mantle Cell Lymphoma: Interim results from a Phase II investigator-initiated study2025
  4. 4Adverse event profiles of acalabrutinib and zanubrutinib in chronic lymphocytic leukemia: A real-world comparison2025 · 1 citations
  5. 5Number of patients needed to treat to prevent one atrial fibrillation event with zanubrutinib versus ibrutinib and acalabrutinib in B-cell malignancies2025